Mitochondrial response of glioma cells to temozolomide

Exp Cell Res. 2023 Dec 15;433(2):113825. doi: 10.1016/j.yexcr.2023.113825. Epub 2023 Oct 21.

Abstract

Metabolic adaptations are central for carcinogenesis and response to therapy, but little is known about the contribution of mitochondrial dynamics to the response of glioma cells to the standard treatment with temozolomide (TMZ). Glioma cells responded to TMZ with mitochondrial mass increased and the production of round structures of dysfunctional mitochondria. At single-cell level, asymmetric mitosis contributed to the heterogeneity of mitochondrial levels. It affected the fitness of cells in control and treated condition, indicating that the mitochondrial levels are relevant for glioma cell fitness in the presence of TMZ.

Keywords: Asymmetric mitosis; Cell fitness; Mitochondria; Mitochondria shape; Temozolomide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Alkylating / pharmacology
  • Apoptosis
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / metabolism
  • Cell Line, Tumor
  • Dacarbazine / metabolism
  • Dacarbazine / pharmacology
  • Dacarbazine / therapeutic use
  • Drug Resistance, Neoplasm
  • Glioma* / drug therapy
  • Glioma* / metabolism
  • Humans
  • Mitochondria / metabolism
  • Temozolomide / pharmacology
  • Temozolomide / therapeutic use

Substances

  • Temozolomide
  • Dacarbazine
  • Antineoplastic Agents, Alkylating